Skip to content

A real-world single center, observational cohort study of early screening markers in gastrointestinal tumors based on open features around the blood cellfreedna promoter

A real-world single center, observational cohort study of early screening markers in gastrointestinal tumors based on open features around the blood cellfreedna promoter

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073150
Enrollment
Unknown
Registered
2023-07-03
Start date
2023-07-15
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal cancer

Interventions

Case series:N/A

Sponsors

The First Affiliated Hospital of Air Force Military Medical University, PLA, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age 18-75 years, sex unrestricted; 2) Patients and their family members agreed and signed informed consent forms. (2) Oncology patient inclusion criteria 1) Did not receive preoperative antineoplastic therapy, samples were collected at surgery and before treatment; 2) Patients with gastrointestinal cancer who were specifically diagnosed by pathology such as histology and / or cytology; 3) No previous comorbid other malignancies;

Exclusion criteria

Exclusion criteria: 1) The patient did not sign the informed consent form or the informed consent form was not compliant; 2) Patients who had received neoadjuvant therapy preoperatively; 3) Previous history of tumors or concurrent other tumors; 4) Pregnant or lactating women; 5) Tumor recurrence; 6) Abnormal coagulation; 7) Acute upper gastrointestinal bleeding; 8) Abnormal liver and kidney function; 9) Subjects who had a blood transfusion 1 month prior to blood draw; 10) Patients who were participating in other clinical trials, or who had participated in other clinical trials with an end of follow-up of less than 1 year; 11) Patients had received any form of oncological treatment including surgery, radiotherapy / chemotherapy, endocrine therapy, targeted therapy and immunotherapy before blood draw at enrollment; 12) HBV, HIV infected patients

Design outcomes

Primary

MeasureTime frame
Single cell transcriptome data;Specific chromatin open intervals;

Countries

China

Contacts

Public ContactJiGang

The First Affiliated Hospital of PLA Air Force Military Medical University

jigang@fmmu.edu.cn+86 135 7215 2581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026